Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein

Japanese Journal of Cancer Research

Volumn 89, Issue 11, 1998, Pages 1220-1228

  Kusunoki, Nobuya ^a   Takara, Kohji ^a   Tanigawara, Yusuke ^a,d   Yamauchi, Aiko ^b   Ueda, Kazumitsu ^c   Komada, Fusao ^a   Ku, Yonson ^a   Kuroda, Yoshikazu ^a   Saitoh, Yohichi ^a   Okumura, Katsuhiko ^a  

^a KOBE UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KEIO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cyclosporin A; Multidrug resistance; P glycoprotein; SDZ PSC 833

Indexed keywords

CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; DOXORUBICIN; GLYCOPROTEIN P; VALSPODAR; VINBLASTINE;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG TRANSPORT; LIPOPHILICITY; NONHUMAN; PRIORITY JOURNAL; TRANSCYTOSIS;

EID: 20244370494     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb00518.x     Document Type: Article

References (30)

1. Endicott, J. A. and Ling, V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem., 58, 137-171 (1989).
2. Gottesman, M. M. and Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385-427 (1993).
3. Fisher, G. A., Lum, B. L., Hausdorff, J. and Sikic, B. I. Pharmacological considerations in the modulation of multidrug resistance. Eur. J. Cancer, 32A, 1082-1088 (1996).
4. Boesch, D., Gavériaux, C., Jachez, B., Pourtier-Manzanedo, A., Bollinger, P. and Loor, F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res., 51, 4226-4233 (1991).
5. Gavériaux, C., Boesch, D., Jachez, B., Bollinger, P., Payne, T. and Loor, F. SDZ PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier. J. Cell Pharmacol., 2, 225-234 (1991).
6. Slater, L. M., Sweet, P., Stupecky, M. and Gupta, S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J. Clin. Invest., 77, 1405-1408 (1986).
7. Twentyman, P. R. Cyclosporin as drug resistance modifiers. Biochem. Pharmacol., 43, 109-117 (1992).
8. Lum, B. L., Fisher, G. A., Brophy, N. A., Yahanda, A. M., Adler, K. M., Kaubisch, S., Halsey, J. and Sikic, B. I. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer, 72, 3502-3514 (1993).
9. Erlichman, C., Moore, M., Thiessen, J., DeAngelis, C., Goodman, P. and Manzo, J. A phase I trial of doxorubicin (D) and PSC 833, a modulator of multidrug resistance (MDR). Proc. Am. Soc. Clin. Oncol., 13, 134 Abstr. 330 (1994).
10. Giaccone, G., Linn, S. C., Catimel, G., Vermorken, J. B., Koier, I., Welink, J., Vijgh, J. W. F., Eeltink, C., Laburte, C. and Pinedo, H. M. Phase I and pharmacokinetic study of SDZ PSC 833 per os in combination with doxorubicin in patients with solid tumors. Proc. Am. Soc. Clin. Oncol., 13, 142 Abstr. 364 (1994).
11. Boote, D. J., Dennis, I. F., Twentyman, P. R., Osborne, R. J., Laburte, C., Hensel, S., Smyth, J. F., Brampton, M. H. and Bleehen, N. M. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol., 14, 610-618 (1996).
12. Sonneveld, P., Marie, J.-P., Huisman, C., Vekhoff, A., Schoester, M., Faussat, A. M., van Kapel, J., Groenewegen, A., Charnick, S., Zittoun, R. and Löwenberg, B. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia, 10, 1741-1750 (1996).
13. Kornblau, S. M., Estey, E., Madden, T., Tran, H. T., Zhao, S., Consoli, U., Snell, V., Shanchez-Williams, G., Kantarjian, H., Keating, M., Newman, R. A. and Andreef, M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J. Clin. Oncol., 15, 1796-1802 (1997).
14. Boesch, D., Muller, K., Pourtier-Manzanedo, A. and Loor, F. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentration of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp. Cell Res., 196, 26-32 (1991).
15. Boekhorst, P. A. W., van Kapel, J., Schoester, M. and Sonneveld, P. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC833 in Chinese hamster ovary cells expressing the mdr1 phenotype. Cancer Chemother. Pharmacol., 30, 238-242 (1992).
16. Keller, R. P., Altermatt, H. J., Nooter, K., Poschmann, G., Laissue, J. A., Bollinger, P. and Hiestand, P. C. SDZ PSC833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int. J. Cancer, 50, 593-597 (1992).
17. Jachez, B., Nordmann, R. and Loor, F. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC833 and the cyclopeptolide SDZ 280-446. J. Natl. Cancer Inst., 85, 478-483 (1993).
18. Chen, G., Jaffrezou, J. P., Fleming, W. H., Duran, G. E. and Sikic, B. I. Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res., 54, 4980-4987 (1994).
19. Jiang, X.-R., Kelsey, S. M., Wu, Y.-L. and Newland, A. C. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC833. Br. J. Haematol., 90, 375-383 (1995).
20. Watanabe, T., Tsuge, H., Oh-hara, T., Naito, M. and Tsuruo, T. Comparative study of reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol., 34, 235-241 (1995).
21. Pourtier-Manzanedo, A., Didier, A. D., Muller, C. D. and Loor, F. SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells. Anti-Cancer Drugs, 3, 419-425 (1992).
22. 1). J. Pharmacol. Exp. The., 263, 840-845 (1992).
23. Ueda, K., Okamura, N., Hirai, M., Tanigawara, Y., Saeki, T., Kioka, N., Komano, T. and Hori, R. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem., 267, 24248-24252 (1992).
24. Okamura, N., Hirai, M., Tanigawara, Y., Tanaka, K., Yasuhara, M., Ueda, K., Komano, T. and Hori, R. Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. J. Pharmacol. Exp. Ther., 266, 1614-1619 (1993).
25. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. and Komano, T. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem., 268, 6077-6080 (1993).
26. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. and Komano, T. P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett., 324, 99-102 (1993).
27. Hirai, M., Tanaka, K., Shimizu, T., Tanigawara, Y., Yasuhara, M., Hori, R., Kakehi, Y., Yoshida, O., Ueda, K., Komano, T. and Inui, K. Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein. J. Pharmacol. Exp. Ther., 275, 73-78 (1995).
28. Tanaka, K., Hirai, M., Tanigawara, Y., Yasuhara, M., Hori, R., Ueda, K. and Inui, K. Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein. Pharm. Res., 13, 1073-1077 (1996).
29. 1 cells transfected with human MDR1 gene. Biochem. Pharmacol., 53, 741-746 (1997).
30. Archinal-Mattheis, A., Rzepka, R. W., Watanabe, T., Kokubu, N., Itoh, Y., Combates, N. J., Bair, K. W. and Cohen, D. Analysis of the interaction of SDZ PSC 833 ([3′-keto-Bmt1]-Val2]-cyclosporin), a multidrug resistance modulator, with P-glycoprotein. Oncol. Res., 7, 603-610 (1995).